The peer-reviewed results of the aducanumab phase 1B study in prodromal and mild AD are now available in Nature. And while some media outlets are touting this...
Read More
Last week, the NYT, WSJ, and Wall Street reacted enthusiastically, if not irrationally, to results of a phase 1B (yes, phase 1B) study of another anti-amyloid MAb (yes,...
Read More
From The Onion‘s “TV Club” (no joke). Blue meth, made (er) popular by TV’s “Breaking Bad,” is on the rise. But the blue coloring of...
Read More
After more than 10 years of research, I am happy (relieved) to announce my soon-to-be published nonfiction book Elixir: The American Tragedy of a Deadly Drug. Look for...
Read More
Matthew Herper of Forbes performs a comprehensive and necessary critical examination of the work of “biotech whiz kid” Jack Andraka. The 16-year-old’s...
Read More
The New York Times, specifically Elizabeth Rosenthal, tries to get behind the outrageous and invariably murky costs of inpatient and ER care. Hospitals claim that...
Read More